MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Progress in the development of small molecules based on the coumarin core as multifunctional neuroprotective agents

M.J. Matos, D. Viña, F. Rodríguez-Enríquez, S. Vilar, L. Santana, E. Uriarte (Santiago de Compostela, Spain)

Meeting: 2016 International Congress

Abstract Number: 1908

Keywords: Cholinesterase inhibitors, MAO-B inhibitors, Neuroprotective agents

Session Information

Date: Thursday, June 23, 2016

Session Title: Parkinson's disease: Clinical trials, pharmacology and treatment

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: Taking into account the background of our research group and the knowledge that MAO and ChE activity generates ROS that cause neuronal cell death, the present work provides an overview about the potential of differently substituted coumarins as multifunctional agents.

Background: MAO and ChE generate ROS that cause neuronal cell death causing neurodegeneration. Agents able to concurrently inhibit MAO, AChE and BuChE, and scavenge free radicals, represent promising multifunctional neuroprotective agents to delay or slow the progression of neurodegenerative diseases.

Methods: Inhibition of MAO-B, AChE and BuChE, scavenging of free radicals, protection of neuronal cells from the H2O2 damage, docking studies and PAMPA assays were carried out. The influence on the activity of the different nature of the substituents introduced at position 3 of the coumarins, is herein studied.

Results: In the current work, differently substituted coumarins that exert neuroprotection in vitro against H2O2 in rat cortical neurons, and antioxidant activity in a DPPH· scavenging assay, are described. Selective and reversible inhibitors of the MAO-B were identified. Slightly inhibition of ChE was also observed for some derivatives. Interestingly, substitution at position 4 with a hydroxy group abolishes the MAO-B activity but the compounds remain active in the neuroprotection model. Further evaluation of the derivatives indicates that the nature of the substitutions can modulate the neuroprotective effects. Evaluation in a PAMPA highlighted the need to further improve the blood-brain permeability of some of the compounds. However, the compounds described here adhere to Lipinski’s rule of five, suggesting that this novel scaffold has desirable properties for the development of potential drug candidates.

Conclusions: Our data suggest sustained effects for the development of small molecules based on the coumarin core as multifunctional neuroprotective agents.

To cite this abstract in AMA style:

M.J. Matos, D. Viña, F. Rodríguez-Enríquez, S. Vilar, L. Santana, E. Uriarte. Progress in the development of small molecules based on the coumarin core as multifunctional neuroprotective agents [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/progress-in-the-development-of-small-molecules-based-on-the-coumarin-core-as-multifunctional-neuroprotective-agents/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/progress-in-the-development-of-small-molecules-based-on-the-coumarin-core-as-multifunctional-neuroprotective-agents/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley